The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting

Advances in Enzyme Regulation

Volumn 41, Issue 1, 2001, Pages 189-207

  Maeda, Hiroshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; BRADYKININ ANTAGONIST; COPOLYMER; ENDOSTATIN; MONOCLONAL ANTIBODY; POLYMER; PROTEINASE INHIBITOR;

ANGIOGENESIS; ANIMAL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES FLUID; BIOLOGICAL MODEL; BLOOD PRESSURE; CANCER PATIENT; CAPILLARY FLOW; CARCINOMATOSIS; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METASTASIS; NEOPLASM; PATHOPHYSIOLOGY; PERMEABILITY; PLEURA FLUID; RETICULOENDOTHELIAL NEOPLASM; SOLID TUMOR; TIME; TISSUE DISTRIBUTION; TUMOR REGRESSION; TUMOR VASCULARIZATION; VEIN;

ANIMALIA;

EID: 0034993240     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(00)00013-3     Document Type: Article

References (59)

1. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
2. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
3. Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor
4. Vascular endothelial growth factor is a secreted angiogenic mitogen
5. Vascular permeability factor, an endothelial cell mitogen related to PDGF
6. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor
7. Tumoritropic and lymphotropic principles of macromolecular drugs
8. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy
9. Polymer conjugated macromolecular drugs for tumor-specific targeting
10. Conjugation of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo
11. The origin of lipoprotein
12. Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention
13. Tumor angiogenesis: Therapeutic implications
14. Angiogenesis
15. 3] bradykinin in ascitic fluid from a patient with gastric cancer
16. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue
17. Kinin-generating cascade in advanced cancer patients and in vitro study
18. Modulation of enhanced vascular permeability in tumors by bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger
19. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both nitric oxide scavenger and nitric oxide synthase inhibitor
20. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth
21. Effect of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model
22. Peroxynitrite and its activated matrix metalloproteinases involved in enhancement of vascular permeability in solid tumor
23. Medial regression and its functional significance in tumor-supplying host arteries
24. Microvascular architecture of experimental colon tumors in the rats
25. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs
26. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image
27. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues
28. Tumor targeting by arterial administration of lipids: Rabbit model with VX2 carcinoma in the liver
29. Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on Smancs
30. Cancer selective macromolecular therapeutics: Tailoring of antitumor protein drugs
31. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic
32. Conjugation of poly(styrene-co-maleic acid) derivatives to antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties
33. Mechanism of localization of gallium-67 in tumors
34. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier
35. Drug targeting in cancer therapy: The magic bullet, what next?
36. Polymer-drug conjugates
37. Bradykinin generation triggered by Pseudomonas protease facilitates invasion of the systemic circulation by Pseudomonas aeruginosa
38. Involvement of bradykinin generation in intravascular dissemination of Vibrio vulnificus and prevention of invasion by a bradykinin antagonist
39. Kallikrein-kinin in infection and cancer
40. Activation of human neutrophil precollagenase by nitrogen dioxide and peroxynitrite: A novel mechanism for procollagenase activation involving nitric oxide
41. Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals
42. 1-protease inhibitor by peroxynitrite
43. A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II
44. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure
45. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril, hydrochloride
46. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer
47. Is there a role for nitric oxide in tumor angiogenesis
48. The codependence of angiogenesis and chronic inflammation
49. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium
50. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report
51. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium
52. Tumor-targeted chemotherapy with SMANCS in Lipiodol for renal cell carcinoma: Longer survival with larger size tumors
53. SMANCS approach - Oily formulation of protein drugs for arterial injection and oral administration
54. Targeting chemotherapy of hepatocellular carcinoma: Arterial administration of SMANCS/Lipiodol
55. Targeting chemotherapy for hepatoma: Arterial administration of anticancer drugs dissolved in Lipiodol
56. Metamorphosis of neocarzinostatin to SMANCS: Chemistry, biology, pharmacology and clinical effect of the first prototype anticancer polymer therapeutic
57. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
58. Phase I Clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylaminde copolymer doxorubicin]: First member of a new class of chemotherapeutic agens - Drug-polymer conjugates
59. 2: Improved stability of SOD in vitro and in vivo